CDK4 and breast cancer: A study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that BRCA2 GPV carriers had poor outcomes following treatment with first-line CDK4/6 inhibitors plus endocrine therapy in 4640 patients with BC whose samples were subjected to germline and matched tumor tissue sequencing using MSK-IMPACT from April 2014 to May 2021.